BioClonetics Immunotherapeutics

BioClonetics Immunotherapeutics

Early Stage

Developing a Cure for HIV

Developing a Cure for HIV


Raised to Date: Raised: $386,766



Start Date


Close Date


Min. Goal
Max. Goal
Min. Investment


Security Type


SEC Filing Type

RegCF    Open SEC Filing

Valuation Cap




Year Founded



Healthcare & Pharmaceuticals

Tech Sector


Heath, Texas

BioClonetics Immunotherapeutics, with a valuation of $10 million, is raising funds on Wefunder. The company is developing the first cure for HIV through the use of monoclonal antibodies. BioClonetics Immunotherapeutics has created a cell line that produces an anti-HIV antibody called Clone 3 that neutralizes all clades and groups of HIV isolates. The company is working with world-class laboratories and expects to complete animal trials within 18 to 24 months. Dr. Joseph Cotropia founded BioClonetics Immunotherapeutics in December 2009. The current crowdfunding campaign has a minimum target of $200,000 and a maximum target of $1 million. The campaign proceeds will be used for the production of the recombinant Clone 3 antibody, testing of the recombinant antibody against HIV isolates, initiation of animal trials, and completion of animal trials.

Summary Profit and Loss Statement

FY 2016 FY 2015












Net Income



Summary Balance Sheet

FY 2016 FY 2015




Accounts Receivable



Total Assets



Short-Term Debt



Long-Term Debt



Total Liabilities



Financials as of: 04/10/2017
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
BioClonetics 11/01/2018 StartEngine $15,000,000 $265,300 SAFE Funded RegCF
BioClonetics Immunotherapeutics 09/29/2017 Wefunder $10,000,000 $386,766 SAFE Funded RegCF
Create a free account today to gain access to KingsCrowd analytics.

Funding data not publicly available

Upgrade to gain access

Pay Monthly
Annually (Save 17%)


$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.

Create your first portfolio

Create your own startup investment portfolio on KingsCrowd.

Track all of your startup investments in one place using our state-of-the-art portfolio tracker tools. To begin, create your first portfolio below.

Add to portfolio
BioClonetics Immunotherapeutics on Wefunder 2017
Platform: Wefunder
Security Type: SAFE
Valuation: $10,000,000

Follow company

Follow BioClonetics Immunotherapeutics on Wefunder 2017

Buy BioClonetics Immunotherapeutics's Deal Report

Warning: according to the close date for this deal, BioClonetics Immunotherapeutics may no longer be accepting investments.

BioClonetics Immunotherapeutics Deal Report

Get KingsCrowd’s comprehensive report on BioClonetics Immunotherapeutics including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether BioClonetics Immunotherapeutics is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the BioClonetics Immunotherapeutics deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge